T 1525/19 (Linagliptin-empagliflozin/BOEHRINGER) of 12.04.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T152519.20240412
- Date of decision
- 12 April 2024
- Case number
- T 1525/19
- Online on
- 23 July 2024
- Petition for review of
- -
- Application number
- 10703474.6
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on EPC2000 Art 056
- Application title
- PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN AND A SGLT2 INHIBITOR,AND USES THEREOF
- Applicant name
- Boehringer Ingelheim International GmbH
- Opponent name
- Generics (U.K.) Limited
STADA Arzneimittel AG
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Teva Pharmaceutical Industries Ltd.
Hexal AG - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 54(3)European Patent Convention Art 56European Patent Convention Art 87(1)Rules of procedure of the Boards of Appeal 2020 Art 013(1)Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Main request - added subject-matter (yes)
Auxiliary request 1 - admitted (yes) - priority (yes) - novelty (yes) - inventive step (yes)
Late-filed document - admitted (no)
Consideration of post-published evidence (yes)
Reopening the debate (no)
Staying the appeal proceedings (no)
Referring questions to the Enlarged Board of Appeal (no) - Catchword
- -
- Citing cases
- T 0314/20
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent in amended form with claims 1 to 14 of auxiliary request 1 as filed with the reply to the statements of grounds of appeal, and a description and drawings to be adapted thereto, if necessary.